Cell therapy · developed by Prokidney
Neo-Kidney Augment is a cell therapy made from expanded autologous selected renal cells derived from the patient's own kidney biopsy, formulated in a gelatin-based hydrogel for administration. It is studied in chronic kidney disease and type 2 diabetes.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT02525263 | Phase 2 | Chronic Kidney Disease | Terminated | PROK |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Chronic Kidney DiseaseType 2 Diabetes
Updated Oct 25, 2026. Something wrong or missing? Report it on the PROK page.
See PROK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PROK catalysts and pipeline →